These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9760807)

  • 21. Thrombin generation and D-dimer concentrations in a patient cohort investigated for venous thromboembolism. Relations to venous thrombosis, factor V Leiden and prothrombin G20210A. The LIST study.
    Chaireti R; Jennersjö C; Lindahl TL
    Thromb Res; 2009 Jun; 124(2):178-84. PubMed ID: 19232683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of single nucleotide polymorphisms on thrombin generation in factor V Leiden heterozygotes.
    Segers O; Simioni P; Tormene D; Castoldi E
    Thromb Haemost; 2014 Mar; 111(3):438-46. PubMed ID: 24226152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation.
    González-Porras JR; García-Sanz R; Alberca I; López ML; Balanzategui A; Gutierrez O; Lozano F; San Miguel J
    Blood Coagul Fibrinolysis; 2006 Jan; 17(1):23-8. PubMed ID: 16607075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular analysis of factor V Leiden, factor V Hong Kong, factor II G20210A, methylenetetrahydrofolate reductase C677T, and A1298C mutations related to Turkish thrombosis patients.
    Dölek B; Eraslan S; Eroğlu S; Kesim BE; Ulutin T; Yalçiner A; Laleli YR; Gözükirmizi N
    Clin Appl Thromb Hemost; 2007 Oct; 13(4):435-8. PubMed ID: 17911197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey.
    Kabukcu S; Keskin N; Keskin A; Atalay E
    Clin Appl Thromb Hemost; 2007 Apr; 13(2):166-71. PubMed ID: 17456626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation.
    Ridker PM; Glynn RJ; Miletich JP; Goldhaber SZ; Stampfer MJ; Hennekens CH
    Ann Intern Med; 1997 Apr; 126(7):528-31. PubMed ID: 9092318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation.
    Brugge JM; Simioni P; Bernardi F; Tormene D; Lunghi B; Tans G; Pagnan A; Rosing J; Castoldi E
    J Thromb Haemost; 2005 Dec; 3(12):2695-702. PubMed ID: 16359508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A.
    Doggen CJ; Cats VM; Bertina RM; Rosendaal FR
    Circulation; 1998 Mar; 97(11):1037-41. PubMed ID: 9531249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
    Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
    Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coexistence of antithrombin deficiency, factor V Leiden and hyperhomocysteinemia in a thrombotic family.
    Gemmati D; Serino ML; Moratelli S; Mari R; Ballerini G; Scapoli GL
    Blood Coagul Fibrinolysis; 1998 Mar; 9(2):173-6. PubMed ID: 9622215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of heterozygosity for the factor V Leiden and factor II G20210A mutations on the risk of thrombosis in Greek patients.
    Hatzaki A; Anagnostopoulou E; Metaxa-Mariatou V; Melissinos C; Philalithis P; Iliadis K; Kontaxis A; Liberatos K; Pangratis N; Nasioulas G
    Int Angiol; 2003 Mar; 22(1):79-82. PubMed ID: 12771861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of placenta-mediated pregnancy complications or pregnancy-related VTE in VTE-asymptomatic families of probands with VTE and heterozygosity for factor V Leiden or G20210 prothrombin mutation.
    Cordoba I; Pegenaute C; González-López TJ; Chillon C; Sarasquete ME; Martin-Herrero F; Guerrero C; Cabrero M; Garcia Sanchez MH; Pabon P; Lozano FS; Gonzalez M; Alberca I; González-Porras JR
    Eur J Haematol; 2012 Sep; 89(3):250-5. PubMed ID: 22642978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Does the asymptomatic carriage of FV Leiden and FII prothrombin in heterozygous configuration represent the increased risk of thrombembolic complications during pregnancy, childbirth and postpartum?].
    Binder T; Vavrinková B; Hadacová I; Hrachovinová I; Salaj P; Hruda M
    Ceska Gynekol; 2012 Feb; 77(1):25-30. PubMed ID: 22536637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
    Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
    Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coexistence of factor V Leiden and Factor II A20210 mutations and recurrent venous thromboembolism.
    Margaglione M; D'Andrea G; Colaizzo D; Cappucci G; del Popolo A; Brancaccio V; Ciampa A; Grandone E; Di Minno G
    Thromb Haemost; 1999 Dec; 82(6):1583-7. PubMed ID: 10613638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia.
    Martinelli I; Battaglioli T; Razzari C; Mannucci PM
    J Thromb Haemost; 2007 Jan; 5(1):98-101. PubMed ID: 17067362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The incidence of venous thromboembolism in carriers of antithrombin, protein C or protein S deficiency associated with the HR2 haplotype of factor V: a family cohort study.
    Tormene D; Fortuna S; Tognin G; Gavasso S; Pagnan A; Prandoni P; Simioni P
    J Thromb Haemost; 2005 Jul; 3(7):1414-20. PubMed ID: 15978097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis.
    Castaman G; Tosetto A; Ruggeri M; Rodeghiero F
    Br J Haematol; 1999 Jul; 106(1):232-6. PubMed ID: 10444192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
    Emmerich J; Rosendaal FR; Cattaneo M; Margaglione M; De Stefano V; Cumming T; Arruda V; Hillarp A; Reny JL
    Thromb Haemost; 2001 Sep; 86(3):809-16. PubMed ID: 11583312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival advantage of heterozygous factor V Leiden carriers in murine sepsis.
    Kerschen E; Hernandez I; Zogg M; Maas M; Weiler H
    J Thromb Haemost; 2015 Jun; 13(6):1073-80. PubMed ID: 25690763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.